T1	Treatment 22 35	immunotherapy
T2	Treatment 111 183	HPV6 L1 virus like particles (VLPs) without adjuvant (VLP immunotherapy)
T3	Treatment 277 284	placebo
T4	Treatment 457 489	conventional destructive therapy
T5	Treatment 525 659	intramuscular administration of 1 µg, 5 µg or 25 µg of VLP immunotherapy, or of placebo immunotherapy (0.9% NaCl), as immunotherapy
